The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
700
Cornea and Cataract Consultants of Arizona
Phoenix, Arizona, United States
Eye Research Foundation
Corneal staining
Mean change from baseline to Day 15 of Inferior Corneal Fluorescein Staining
Time frame: 15 days after first dosing
Ocular Discomfort 6-point (0=none, 5=worst) scale
Mean change from baseline to Day 15 of Ocular Discomfort severity
Time frame: 15 days after first dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Newport Beach, California, United States
Vision Institute
Colorado Springs, Colorado, United States
Dovilan Wyatt MD, LLC
Chicago, Illinois, United States
Whitson Vision
Indianapolis, Indiana, United States
Midwest Cornea Associates, LLC
Indianapolis, Indiana, United States
The Eye Care Institute
Louisville, Kentucky, United States
Andover Eye Associates
Andover, Massachusetts, United States
Andover Eye Associates
Raynham, Massachusetts, United States
Center For Sight
Henderson, Nevada, United States
...and 10 more locations